Covance, Sihuan Pharma Partner on Preclinical/Clinical Portfolio Development
Under an agreement with LabCorp and Shandong XuanZhu Pharma, the wholly-owned subsidiary for drug R&D of China-based Sihuan Pharmaceutical, Covance will support the preclinical and clinical development of the pharma's pipeline, which includes new molecules across a range of therapeutic areas, including cardiovascular, metabolic, infectious disease, oncology and urology. Specifically, Covance will provide Sihuan Pharmaceutical with global drug development and regulatory expertise, particularly in efforts to achieve dual or multiple filings for regulatory approvals such as investigational new drug (IND) applications and new drug applications (NDA) in China and internationally.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
